Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAlgorae Pharmaceuticals Ltd

Algorae Pharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.009 AUD 0.00 ( 12.50%)
Last update at 2026-11-10T23:02:00Z
VOLUME
88236
Market Cap
18.25M

Momentum Score

…

Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development; and AlgoraeRx, a commercial pharmaceutical division that source generic and specialty medicines from manufacturers. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Algorae Pharmaceuticals Ltd is an ASX-listed small-cap pharmaceutical company with limited publicly available detail on its operations and pipeline, and it appears to be at an early development stage. Long-term growth may depend on successful clinical development, regulatory approvals and potential licensing or partnership activity, which could support value creation for investors.
Principal investment risks include early-stage clinical and regulatory failure, ongoing funding requirements and attendant dilution, low trading liquidity and sector-specific competitive and execution risks.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.14M
Revenue Per Share
-
Gross Profit TTM
0.14M
Debt / Equity
-
ROE
-83.53%
Net Debt
-3.19M
ROCE
-73.72%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -3.10M -1.54M -2.10M -2.11M -2.37M
Net income -2.71M -0.80M -2.10M -2.11M -1.96M
Selling general administrative - 0.84M 1.31M 0.82M 0.91M
Reconciled depreciation - - - 0.00M 0.00M
Ebit - - - -2.13M -2.36M
Ebitda -3.14M -1.54M -2.20M -2.13M -2.36M
Depreciation and amortization - - - 0.00M 0.00M
Operating income -3.14M -1.69M -2.20M -2.13M -2.36M
Other operating expenses 3.14M 1.69M 2.20M 2.13M 2.38M
Interest expense - - - - 0.00M
Tax provision - -0.74M 0.00M 0.00M -0.41M
Interest income - 0.02M 0.02M 0.04M 0.00M
Net interest income - - 0.13M 0.04M 0.00M
Income tax expense -0.38M -0.74M - -0.04M -0.41M
Total revenue - 0.14M 0.13M 0.04M 0.00M
Total operating expenses 3.14M 1.69M 2.20M 2.13M 2.38M
Total other income expense net 0.05M 0.15M 0.11M -0.02M -0.01M
Net income from continuing ops - - -2.10M -2.11M -1.96M
Net income applicable to common shares - -0.80M -2.10M -2.11M -1.96M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 4.44M 2.40M 3.19M 4.21M 4.27M
Other current assets 0.24M 0.04M 0.04M - -
Total liab 0.18M 0.17M 0.18M 0.45M 0.24M
Total stockholder equity 4.26M 2.23M 3.01M 3.76M 4.03M
Other current liab 0.09M - - 0.27M 0.19M
Common stock 85.47M 81.54M - 80.24M 78.95M
Capital stock - - 81.54M 80.24M 78.95M
Retained earnings -82.06M -79.31M -79.08M -80.73M -78.74M
Cash 3.19M 0.47M 3.11M 4.11M 4.24M
Total current liabilities 0.18M 0.17M 0.18M 0.45M 0.24M
Net debt -3.19M - - -4.11M -4.24M
Short term debt - 0.00M - 0.00M 0.00M
Other stockholder equity - - - 4.25M 3.83M
Property plant equipment - 0.00M - 0.00M 0.01M
Total current assets 4.44M 2.40M 3.19M 4.21M 4.27M
Net tangible assets - - - 3.76M 4.03M
Short term investments 0.75M 1.85M - 0.00M 0.00M
Net receivables 0.08M 0.04M - 0.10M 0.03M
Inventory 0.18M - - - -
Accounts payable 0.09M - 0.12M 0.18M 0.05M
Accumulated other comprehensive income 0.85M - - 4.25M 3.83M
Non current assets total - - 0.00M 0.00M 0.01M
Long term debt total - 0.00M - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -0.28M - 0.04M
Change to liabilities - - - 0.16M 0.03M
Total cashflows from investing activities 1.10M 0.45M -0.28M 0.00M 0.04M
Net borrowings - - - - 2.29M
Total cash from financing activities 4.22M -0.00M 0.52M 1.85M 4.69M
Change to operating activities - - - 0.01M -0.05M
Net income -2.71M -0.80M -2.10M -2.11M -1.96M
Change in cash 2.72M -2.64M -1.00M -0.13M 2.67M
Begin period cash flow 0.47M 3.11M 4.11M 4.24M 1.57M
End period cash flow 3.19M 0.47M 3.11M 4.11M 4.24M
Total cash from operating activities -2.60M -0.79M -1.52M -1.99M -1.96M
Issuance of capital stock - - 0.57M 2.15M 2.86M
Depreciation - - - 0.00M 0.00M
Other cashflows from investing activities - 0.45M -0.28M 0.00M 0.04M
Change to inventory -0.18M - - - -
Change to account receivables -0.04M 0.01M 0.05M -0.07M -0.02M
Sale purchase of stock - 0.00M 0.57M 2.15M 2.86M
Other cashflows from financing activities - -0.00M -0.05M -0.30M 1.83M
Change to netincome - - - 0.02M -0.04M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.39M -0.00M -0.21M 0.03M 0.00M
Other non cash items 0.49M 0.02M 0.79M - 1.96M
Free cash flow -2.60M -0.79M -1.52M -1.99M -1.96M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
1AI
Algorae Pharmaceuticals Ltd		 0.00
12.50%		 0.01 - - 2705.69 4.28 3010.88 -3.72
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Algorae Pharmaceuticals Ltd

Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development; and AlgoraeRx, a commercial pharmaceutical division that source generic and specialty medicines from manufacturers. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.

Rialto South Tower, Melbourne, VIC, Australia, 3000

61 2 9698 5414

https://algoraepharma.com

Name Title Year Born
Dr. Bernard Tuch B.Sc., BSc, FRACP, GAICD, MBBS, MBBS (Hons), Ph.D. Interim Chief Exec. Officer 1951
Mr. Daya Uka Chief Financial Officer NA
Dr. Belinda Di Bartolo Chief Operations Officer NA
Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP Company Sec. 1964
Mr. David Richard Hainsworth CEO & Executive Chairman 1973
Mr. Daya Uka B.Com., C.A. Chief Financial Officer NA
Dr. Carolyn M. Sue A.M., B.S., Ph.D. Member of Medical Advisory Board & Chief Medical Officer of NTCELL 1963
Dr. James A. Mckenna Chief Scientific Officer NA
Ms. Leah Pieris Company Secretary NA
Mr. David Richard Hainsworth CEO & Executive Chairman 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…